These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27774015)

  • 1. Schizophrenia Outpatient Health Outcomes study: twelve-month findings.
    Novick D; Ascher-Svanum H; Haro JM; Bertsch J; Takahashi M
    Pragmat Obs Res; 2012; 3():27-40. PubMed ID: 27774015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Haro JM; Edgell ET; Novick D; Alonso J; Kennedy L; Jones PB; Ratcliffe M; Breier A;
    Acta Psychiatr Scand; 2005 Mar; 111(3):220-31. PubMed ID: 15701107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Novick D; Haro JM; Perrin E; Suarez D; Texeira JM
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):542-50. PubMed ID: 19500949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.
    Hong J; Novick D; Brugnoli R; Karagianis J; Dossenbach M; Haro JM
    BMC Psychiatry; 2012 Dec; 12():218. PubMed ID: 23206324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].
    Meder J; Debowska G; Lis J; Araszkiewicz A; Sierosławska K; Kolesaric A; Treuer T
    Psychiatr Pol; 2004; 38(3):469-84. PubMed ID: 15199656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].
    Brunner E; Gargoloff P; Caro O; González C; Landa E; González CH; Barahona A; Soria D; Tamayo J; Rovner J; Adrianzen C; Silva H; Hodge A; O'Halloran R; Assunção SS;
    Actas Esp Psiquiatr; 2006; 34(1):16-27. PubMed ID: 16525901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
    Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
    Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Gasquet I; Haro JM; Novick D; Edgell ET; Kennedy L; Lepine JP;
    Int Clin Psychopharmacol; 2005 Jul; 20(4):199-205. PubMed ID: 15933480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
    Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
    Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the findings from the European SOHO study.
    Suarez D; Haro JM
    Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Lee P; Eung Kim C; Yoon Kim C; Lin WW; Habil H; Dyachkova Y; Mcbride M; Dossenbach M
    Int J Psychiatry Clin Pract; 2008; 12(3):215-27. PubMed ID: 24931661
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.